Launching as a RUO Kit and LDT service in August 2023
Visit our scientists at poster presentation: 0-03-02 titled “Validation of epiHERA®, a minimally invasive PCR tool for hypermethylated CDO1/CELF4 genes associated with endometrial cancer”, or hear our oral presentation on 19 June, 1430-1445 Abstract Session 3, at AMP Congress 2023 in Milan to learn more about it.
Partnerships are vital for continued medical advancements. We constantly seek collaborators to:
6 Raffles Quay
#14-04/05
Singapore 048580
1 Science Park Road
#04-10 The Capricorn
Singapore 117528
Please note that the contents of this website are for corporate and non-commercial information purposes only and are provided on the understanding that no surgical or medical advice or recommendation is being rendered. Please refer to our website Terms of Use. The content of this site may not be construed as advertisements for any product or service that INEX or any of its subsidiary companies offers.
© 2023 INEX INNOVATE PRIVATE LIMITED. ALL RIGHTS RESERVED. 0009-0302-00.
A simple sample collection using the common HPV swab is taken and the DNA is extracted. The extracted DNA undergoes bisulfite conversion before an accurate method of screening through real-time PCR analyses. The bisulfite conversion functions by converting unmethylated Cytosine nucleotides to Uracil, which is then converted to Thymine by PCR. Conversely, the methylation mark protects the methylated Cytosine nucleotides from being converted to Uracil.
